



UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
631 PARK AVENUE
KING OF PRUSSIA, PENNSYLVANIA 19406

Docket No. 30-14826

NOV 14 1979

Pharmatopes, Inc.
ATTN: Mr. Robert Erwin
Vice President
4545 42nd Street, N.W.
Washington, D.C. 20016

Gentlemen:

Subject: Inspection 30-14826/79-02


Reference: Your letter with addenda dated October 17, 1979, in response to our letter dated September 27, 1979.

Thank you for informing us of the corrective and preventive actions you documented in response to our correspondence. However, your letter has been reviewed and additional information is found to be needed.

1. In response to item B.3, you failed to provide assurance that your dose calibrator will be adjusted or repaired when activities measured during linearity tests differ by more than 5 percent. If you wish to increase this action limit to 10 percent you must submit an application to amend your license to the NRC's License Management Branch for review and approval.
2. With regard to item B.4, please specify how you will assure that wipe tests of packages recorded in counts per minute do not exceed the activity limits in 10 CFR 20.205(b)(2).

Please respond to this office within seven (7) days of receipt of this letter a written statement containing the requested information.

Sincerely,


Robert O. McClintock, Chief
Materials Radiological Protection
Section

2178 210

8001020

078